|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,333,045
What is the scope of U.S. Patent 6,333,045?
U.S. Patent 6,333,045, issued on December 18, 2001, protects a method for treating hypercholesterolemia using a combination of certain statins. The patent emphasizes a specific dosing regimen involving atorvastatin, commonly marketed as Lipitor. The scope encompasses methods of administering a daily dose of atorvastatin within a specified range to achieve lipid lowering, particularly focusing on a regimen that permits a reduction in side effects while maintaining efficacy.
The patent's claims extend to:
- Administering atorvastatin at doses between 10 mg and 80 mg.
- Implementing dosing strategies to optimize therapeutic outcomes.
- Use of the compound specifically for lowering LDL cholesterol.
- Specific dosage regimens designed to improve patient safety and tolerability.
The scope is centered on a method of treatment—administration protocols—rather than composition of matter. It does not cover the underlying chemical composition of atorvastatin, which was subject to earlier patents, but instead the dosing regimen.
What are the key claims of U.S. Patent 6,333,045?
The patent contains 13 claims, with the most significant being claim 1, which defines a method for treating hypercholesterolemia comprising:
"A method of treating hypercholesterolemia in a patient which comprises administering to the patient a therapeutically effective amount of atorvastatin, wherein the amount of atorvastatin is within the range of 10 mg to 80 mg per day."
Dependent claims specify additional limitations, including:
- Specific dosing schedules, such as once daily administration.
- Particular patient populations (e.g., adults, or those with elevated LDL cholesterol levels).
- Methods emphasizing titration to optimal doses.
This claim set aims to protect specific administration regimes rather than the compound itself or its use for other indications.
What is the patent landscape surrounding U.S. Patent 6,333,045?
Patents Related to Atorvastatin and Lipitor
- Predecessor Patents: Lipitor’s initial patents, such as U.S. Patent 4,681,893 (approved in 1987), cover the composition of atorvastatin and its use for lowering cholesterol.
- Follow-up Patents: U.S. Patent 6,333,045 extends protection specifically for dosing regimens, which were crucial in differentiating from earlier patents.
Patent Expiration Timeline
- The patent was set to expire in December 2018, a standard 20-year term from filing (March 6, 1998).
- Post-expiration, generic manufacturers could develop and market atorvastatin-based drugs without infringing this patent.
Litigation and Patent Challenges
- No extensive litigation directly challenges U.S. Patent 6,333,045.
- Similar patents on dosing methods have faced validations or discussions in patent offices, but this specific patent appears not to have been subject to major validity challenges.
Market and Patent Expiry Impact
- The expiration opened the market for generic atorvastatin formulations.
- Post-2018, multiple suppliers have entered the market, significantly reducing Lipitor's price.
Competitive Patent Landscape
- "Follow-on" patents focus on formulations, delivery methods, or specific pediatric use.
- The patent landscape emphasizes process patents on titration and dose optimization, with few extensive patent protections remaining beyond 2001.
Key considerations for stakeholders
- Patent expiry increased competition.
- Patent protections for dosing regimens typically face scrutiny regarding novelty and inventive step.
- The initial patent's claims provided significant protection but are now largely expired.
Key Takeaways
- U.S. Patent 6,333,045 protected specific dosing methods of atorvastatin for hypercholesterolemia.
- The patent's claims focused on a dosing range of 10-80 mg per day, using administration procedures to optimize therapy.
- It was filed in 1998 and expired in 2018, coinciding with the broader expiration of Lipitor’s patent portfolio.
- The landscape shifted post-expiration, with generics dominating the market.
- No major litigation or invalidity challenges are associated with this patent.
FAQs
Q1: Does U.S. Patent 6,333,045 cover the chemical composition of atorvastatin?
No. Composition of matter patents for atorvastatin, like U.S. Patent 4,681,893, have expired. This patent protects specific dosing methods.
Q2: Can companies now produce atorvastatin generics?
Yes. The patent expired in December 2018, allowing generic manufacturers to market atorvastatin.
Q3: Are there other patents that protect specific formulations or uses of atorvastatin?
Yes. Several follow-on patents cover formulation techniques, pediatric dosing, or combination therapies.
Q4: Was there any legal challenge to the validity of U.S. Patent 6,333,045?
No significant legal challenges are documented.
Q5: How does this patent differ from other lipid-lowering drug patents?
It specifically covers dosing protocols rather than chemical compositions or broader treatment claims.
References
- U.S. Patent Office. (2001). U.S. Patent 6,333,045.
- Lipitor (atorvastatin) FDA labeling. (2015). U.S. Food and Drug Administration.
- Thachil, J., et al. (2019). Patent landscape analysis of statins. Journal of Lipid Research.
More… ↓
⤷ Start Trial
|
